Semaglutide: Key Differences and Synergies The comparison of Cagrilintide vs semaglutide highlights how dual-pathway modulation may offer more robust results than single-agent approaches alone
However, most patients who discontinue GLP-1s either maintain their weight loss or regain slowly, and the facial fat pads do not reliably replenish through weight regain alone
These agents act through multiple mechanisms, including direct cardioprotection, vasodilation, natriuresis, weight reduction, lipid profile improvement, anti-inflammatory effects, renal protection, reduction in plaque formation, and neurohormonal regulation
Interestingly, while tirzepatide acts as an agonist of the GLP-1 receptor, it may effectively act as a GIP receptor antagonist
Relatively, exenatide ER was therefore considered 65% as efficacious as once-weekly semaglutide 1.0 mg at bringing patients to target, while dulaglutide 0.75 mg and 1.5 mg were respectively 79% and 97% as efficacious as once-weekly semaglutide 0.5 mg, and 70% and 87% as efficacious as once-weekly semaglutide 1 mg in bringing patients to an HbA1c of lower than 7.0% (Figs